DEVELOPMENTAL RESEARCH PROGRAM

DRP 主任：约翰伦纳德，医学博士（WCMC） 联合导演：Anas Younes（MSK） DRP总结 发展研究计划（DRP）将确定新的机会，以支持医生和 科学家，并鼓励他们利用自己的专业知识，开发新的转化研究思路， 淋巴瘤DRP将提供种子资金，以产生和探索新的假设， 随后扩大和淋巴瘤孢子内的完整项目测试，或通过其他孢子- 经独立同行审查的外部赠款支助。SPORE DRP的目的是开发翻译 研究项目，应导致可测试的假设，旨在改善诊断和治疗 淋巴瘤每年将向所有参与机构分发征求建议书。 选定的提案（每年1-2个）将得到50，000美元的SPORE预算的支持， 机构支持。资助期限为1年。根据第一年的成绩， 经EAB审查，资金可延长第二年。美国国立卫生研究院的审查标准将用于 选择项目。代表性不足的少数民族和女性申请人的提案将特别 恳求。该计划利用了一个强大的研究小组与记录的科学记录 以及所有三个参与机构的出色基础设施，纪念斯隆凯特琳癌症中心 (MSK)、威尔-康奈尔医学院（WCMC）和哥伦比亚大学医学中心/赫伯特欧文 综合癌症中心。

DRP Director: John Leonard, MD (WCMC) Co-Director: Anas Younes (MSK) DRP SUMMARY The Developmental Research Program (DRP) will identify new opportunities to support physicians and scientists, and encourage them to use their expertise to develop novel translational research ideas in lymphoma. The DRP will provide seed funding to generate and explore new hypotheses that may subsequently be expanded and tested as full project within the Lymphoma SPORE, or through other SPORE- independent peer-reviewed external grant support. The purpose of the SPORE DRP is to develop translational research projects that should result in testable hypotheses aimed at improving the diagnosis and treatment of lymphoma. On an annual basis, a request for proposals will be distributed to all participating institutions. Selected proposals (1-2 annually) will be supported with $50,000 of the SPORE budget with matching institutional support. Funding will be awarded for 1 year. Based on accomplishments during the first year, and review by the EAB, funding may be extended by a second year. Usual NIH review criteria will be used in selection of projects. Proposals from underrepresented minority and female applicants will be specifically solicited. The program takes advantage of a strong group of investigators with documented scientific record and outstanding infrastructure at all three participating Institutions, Memorial Sloan Kettering Cancer Center (MSK), Weill-Cornell Medical College (WCMC) and the Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.